Almost 78 000 new cases of CNS tumors are diagnosed every year in the United States, with nearly 17 000 lives lost annually to this disease. 1 Despite research efforts and advances in diagnostic and therapeutic strategies, the mortality and morbidity of these tumors remain high. 2 CNS tumors pose a particular challenge from both a research and a clinical standpoint. The unique features of the bloodbrain barrier complicate the delivery of therapeutic agents into the CNS and make it difficult to readily translate findings from other cancer fields. 3 Moreover, with over 100 subtypes of CNS tumors, patient enrollment into clinical trials is a challenge, as the incidence of a distinct tumor subtype is relatively low.
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combined with resource scarcity implies that scientific endeavor can benefit from better focusing on the field's greatest needs. Reflecting on historical trends in neurooncology research and examining the literature that has made a significant impact in the field can provide insight into scientific progress over time and identify areas of greatest interest along with those that have been understudied. In the realm of bibliometric research, citation counts are commonly used as a measure of scientific impact. The term "citation classics" has been developed to describe articles with at least 400 citations. 4 These highly cited works often represent landmarks of the literature that have gained recognition by researchers in the field and laid the groundwork for important clinical and research discoveries. 5, 6 Examining citation classics in a field facilitates identification of important literature and provides insight into research trends over time. Here we present the first report of the citation classics in the field of neuro-oncology.
Methods

Search Strategy and Selection Criteria
A search of the Web of Science database was conducted on October 1, 2016 using the following terms: [(brain tumor)OR(brain neoplasm)OR(spine tumor)OR(spine neoplasm)OR(spinal tumor)OR(spinal neoplasm)OR(neurooncology)OR(neurooncology)OR(brain cancer)OR(medulloblastoma)OR(glio*)OR(meningioma)OR(cerebellar neoplasm)OR(cerebral neoplasm)]. The Web of Science database, which indexes only ISI journals, was chosen for the search, as it does not include citations from nonscholarly sources, thus avoiding the possibility of inflated citation counts. While databases such as Google Scholar may have a broader scope of indexing, they also include nonscholarly citations, and thus utilization of the Web of Science database produces a more relevant list of highly cited works.
No restrictions were placed on publication date (database coverage included 1900-present), language, or study type. Records with <400 citations were excluded. Articles were first screened by title for their relevance to neurooncology, and remaining articles underwent abstract review. Articles not directly pertaining to neuro-oncology were excluded. Among the final list of studies obtained, the top 100 cited articles were included in the final analysis ( Supplementary Fig. S1 ).
Data Collection
The following parameters were extracted from each article: country, journal, tumor type, citation count. Country of origin was based on the affiliation of the corresponding author. Articles were classified by study design, investigational approach, and topical theme. Article types consisted of clinical papers (retrospective, prospective, or randomized), laboratory investigations, reviews/metaanalyses, and guidelines/consensus statements. In order to assess trends in the literature, articles were classified on the basis of their primary theme. These themes were chosen to represent major areas of neuro-oncology research and encompass important aspects relevant to clinical practice. The themes included: classification, pathogenesis/clinical presentation, imaging, and therapy. Therapy-related articles were subclassified into those primarily pertaining to chemotherapy, radiation, surgery, or newer agents. Newer agents included all other therapies aside from standard chemotherapy, radiation, and surgery, including new drug delivery methods, gene therapy, anti-angiogenic strategies, and target-specific intracellular molecule inhibitors.
Statistics
Correlational analyses between continuous variables were conducted using SigmaStat Software. A P-value < 0.05 was considered significant.
Results
Based on the search strategy, the top 100 neuro-oncologyspecific citation classics were obtained ( Table 1 ). The number of times that articles were cited ranged from 565 to 6379 with a median of 815 citations.
Source
The citation classics were published in 36 different journals (Table 2 ). Journals were classified into 4 main categories. Forty-three articles were published in general medical/scientific journals, 37 articles in oncology-specific journals, 11 articles in neuroscience-specific journals, and 9 articles in various other journals. There was a significant, but not strong, correlation between journal impact factor and number of citation classics published in a given journal (Pearson coefficient = 0.5759, P = 0.0002). North American institutions produced the majority of the citation classics (71 articles), with the United States leading the list with 68 articles (Table 3) . Twenty-five articles were from European centers (Germany, Switzerland, France, UK, Italy).
Study Types
A breakdown of the different study types among the citation classics is provided in Table 4 . Forty-three citation classics were clinical studies-specifically, 17 were retrospective analyses, 10 were prospective analyses, and 16 were randomized trials. Of the clinical studies, 7 investigated associations between tumor molecular-genetic markers and patient outcomes. Forty-three citation classics were laboratory investigations, and among these: 8 studies involved molecular-genetic analyses of patient samples that were correlated with clinical outcomes, 19 involved in vivo animal models, and 16 examined tumorderived samples or cell lines. Eight studies were reviews/ meta-analyses and 6 articles were guidelines/consensus statements. 
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Themes
The citation classics were categorized into 4 major themes, which represent key areas of research in neuro-oncology: (1) classification, (2) pathogenesis and clinical presentation, (3) imaging, and (4) therapy (Table 4) . 
Pathogenesis and clinical presentation
Thirty-seven citation classics focused on tumor pathogenesis or clinical presentation. Six studies reviewed general clinical features and presentation of brain tumors. Among pathogenesis-related articles, there were 2 etiological studies, which demonstrated a link between radiation exposure and brain tumor development. Twenty studies described molecular or genetic features that may predict tumor aggressiveness, malignancy, or treatment response. Among these, 4 studies focused on the role of epidermal growth factor (EGR) receptors; 2 on micro RNAs; 2 on isocitrate dehydrogenase mutations; 2 on p53 mutations; 1 on the role of vascular endothelial growth factor; 1 on inhibitor of DNA binding protein (ID)1/ID3; 1 on the phosphatidylinositol-3 kinase pathway; and 6 on general pathways involved in tumorigenesis. Eight studies examined characteristics of brain cancer stem cells and their role in tumor pathogenesis. One study looked at genetic distinctions between primary and secondary glioblastoma multiforme (GBM).
Imaging
There were 6 citation classics pertaining to imaging of CNS tumors. Four studies examined PET or MRI techniques in order to measure tumor grade and treatment response. The remaining 2 studies included the original and updated consensus statements on malignant glioma response criteria involving radiographic findings. 
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Tumor Types
Gliomas were the most common tumor type examined across the citation classics, with 70 articles accruing a total of 75 491 citations (Table 5 ). Of these, 56 studies specifically focused on malignant/high-grade gliomas (HGGs). Ten studies examined metastases, 2 were specifically about spinal metastases, and 2 studies examined meningiomas.
Temporal Trends
There was a steep increase in the number of citation classics in the late 1990s, with a decrease in the most recent epoch (2008) (2009) (2010) (2011) (2012) (Fig. 1A) . This increase largely comprised articles pertaining to tumor pathogenesis along with therapies (Fig. 1B) , particularly those focusing on chemotherapy and newer agents (Fig. 1C) . There was also an increase in the number of laboratory studies and randomized trials since the late 1990s (Fig. 1D ). There was a negative correlation between the average number of citations per year and the number of years since publication for articles; Pearson coefficient = −0.2632, P = 0.007 ( Supplementary Fig. S2 ). Fig. 2 highlights a selection of the citation classics that have had major impact on clinical practice in the field of neuro-oncology over time.
Discussion
In this study, we present the first analysis of the citation classics in neuro-oncology. Through a focused review of the literature we found that the majority of citation classics pertained to gliomas and metastases, with a significant focus on tumor pathogenesis and therapeutic strategies.
Moreover, in recent years there has been an increase in citation classics examining fundamental pathways in the tumor disease process, chemotherapeutics, and new pharmacological agents, along with laboratory studies and randomized trials.
Characteristics and Trends in the Citation Classics
As gliomas are among the most common primary brain tumors, it is not surprising that over half of the citation classics examined this tumor type. The aggressive nature of HGGs, in particular GBM, has made treatment difficult, and despite current therapies, prognosis remains poor. 2 Many citation classics pertaining to gliomas or GBM focused on tumor pathogenesis and new therapeutic strategies, suggesting that there has been significant scientific interest around establishing improved therapies for this tumor. Moreover, clinical trials investigating GBM are facilitated by the fact that clinical endpoints are often reached earlier than tumors that take a more indolent course. Further investigation to elucidate key drivers of the aggressive biology of these tumors and susceptibility to novel targeted therapies will likely be key in improving patient survival.
Only 2 citation classics examined meningiomas despite their accounting for nearly 30% of all brain tumors. As meningiomas are often benign and outcomes of interest such as survival occur on a greater time scale, malignant gliomas have historically received more research funding and scientific attention. 7 However, a subset of meningiomas exhibit aggressive behavior that poses significant challenges with regard to optimal management and quality of life. 8 In addition, only 10 studies examined CNS metastases. Similar to malignant gliomas, the prognosis of CNS metastases is often poor and many questions remain regarding optimal treatment, including the role of stereotactic radiosurgery versus whole-brain radiotherapy for multiple intracranial metastases and the use of targeted treatments and chemotherapeutics to cross the blood-brain barrier. Despite this, CNS metastases have received significantly less research attention compared with gliomas, highlighted by disparity in citation classics identified in this study compared with gliomas. Thus, the field may benefit from increased resources and research efforts directed toward better understanding and treating these tumor types.
The wide disparity in citation classics between the United States and other countries is consistent with previous reports examining brain tumor research output across countries and may be attributed to differences in total research output, resource allocation, and funding structures. 9 Total spending on brain research in 2005 was approximately 4 times higher in the United States than in Europe. A breakdown of funding structures revealed that nearly 39% of brain research in the United States was government funded compared with 16% in Europe. 10 Increased funding and allocation of government resources toward neuro-oncology research may facilitate research output.
There was a significant, but not strong, correlation between journal impact factor and the number of citation classics published in a given journal. Journal type may not 
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necessarily reflect the impact of an individual article, and therefore analyzing citation classics is important to help establish benchmarks for high impact within a field.
Although the majority of citation classics were original research articles, 2 articles were meta-analyses and 6 were literature reviews. Meta-analyses can have a significant 
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impact on clinical and research directions within a field, as they provide high-level evidence, deriving important conclusions from multiple smaller studies that may lack statistical power or have conflicting outcomes. While literature review articles may not contribute original data to the field, we included them in our search, as they can integrate unique findings from many studies which individually may not have accrued a high number of citations, but a synthesis of their findings can produce an important overview of the current state of the field and thus enhance understanding of a topic. In areas where there is limited existing scientific evidence on a topic, review articles may also incorporate important expert opinion that can inform patient management and future research direction.
The dominance of articles related to chemotherapy and "new agents, " especially in recent epochs, may reflect shifts in research interests among the scientific community over time. Historically, both surgery and later radiotherapy received much attention and were established early on as effective therapies for various CNS tumors. While interest may have therefore shifted away from evaluating these methods, there still remain important clinical questions regarding extent of surgical resection and reresection, optimal radiation protocols for metastases, and ideal timing of radiation for low-grade glioma. In contrast, the survival benefit of chemotherapy for GBM was more recently established 2 and thus has gained scientific interest in recent epochs, particularly surrounding methods to optimize delivery of chemotherapeutic agents or identify markers that predict chemoresistance or chemosensitivity. Moreover, interest in new agents may have increased in response to the need to develop adjuncts to standard therapies given the poor prognosis of malignant brain tumors.
There was a steep rise in the number of citation classics in the late 1990s, which may be due to a number of factors. The increase in citation classics was paralleled by an increase in the number of laboratory and randomized studies, suggesting that high-quality clinical studies and fundamental investigations into disease processes are seen in a higher regard by the scientific community. Recent studies have emphasized the need for high-quality randomized controlled trials (RCTs) in neuro-oncology and neurosurgery research. 11,12 A similar "90s peak" has been reported in previous analyses of citation classics in other disciplines 13, 14 and may be in part a result of older work representing established principles that are no longer cited and newer work having insufficient time to accumulate citations. Moreover, the latter part of the late 90s peak may also reflect improved indexing in online databases which occurred around 2005 as previously reported, 15, 16 along with an expansion in the number of investigators conducting research in the field, which may yield increased citation counts among more recent papers. We found that there was a negative correlation between the number of citations per year and the year since publication of an article. This is consistent with previous reports examining citation classics in other fields suggesting that the citation timeline of a scientific article often takes a predictable course. Citations are generally accrued about 2 years after publication, reaching a peak after 3-10 years, then declining in the rate of citations thereafter. 17, 18 This trend may also in part explain the decline in the total number of citation classics observed in the most recent epoch, as citation counts for some articles published during this time would be expected to peak in the years following our analysis.
Landmark Advances in Neuro-Oncology
The list of citation classics includes a set of seminal articles which have had major impact on clinical practice in the field of neuro-oncology and can serve as fundamental reading to guide the education of early trainees. Many of the early citation classics in neuro-oncology were dedicated to the histological classification of brain tumors. [19] [20] [21] More recently there has been a surge in genetic and molecularbased classification systems, which has been facilitated by advancements in biomedical techniques. This is borne out by landmark changes in the new 2016 WHO guidelines, which include for the first time the use of molecular parameters to define tumors. 22 Moreover, seminal work on tumor pathogenesis helped elucidate genetic alterations underlying tumor malignancy states 23, 24 and the role of cancer stem cells. 25, 26 Refined genetic and molecular classification systems and increased understanding of tumor pathogenesis will help inform the design of future clinical trials with a rational selection of patients for specific experimental protocols, which will hopefully improve the rate of positive trials.
Seminal discoveries pertaining to the treatment of CNS tumors largely paralleled shifts in clinical practice. One of the earliest RCTs, conducted in 1978 by Walker et al, established radiotherapy as a part of the standard of care for patients with malignant gliomas. 27 Almost a decade later, Patchell et al conducted the first RCT to show that surgery in combination with radiotherapy is superior to radiotherapy alone for single brain metastases, which revolutionized the field. 28 The 1990s witnessed the emergence of genetic-based studies, and in 1998 Cairncross et al demonstrated that anaplastic oligodendrogliomas with loss of chromosome 1p and 19q had increased susceptibility to chemotherapy, thus marking the beginning of the era of "personalized therapies" in neuro-oncology. 29 At the same time, chemotherapeutic agents for CNS tumors continued to have an impact in the field. In 2003, Westphal et al demonstrated that local delivery of the chemotherapeutic agent BCNU at the time of surgery for malignant glioma increased survival. 30 In 2005, Stupp et al laid the groundwork for the current standard of treatment for GBM showing that temozolomide chemotherapy plus radiotherapy has significant survival benefit for GBM. 2 In the same year, Hegi et al showed that gene silencing of O 6 -DNA methylguanine-methyltransferase (MGMT) improves response to temozolomide in GBM, further highlighting the need for personalized treatments. 2 Although surgical technique has not seen as dramatic an interest as laboratory-based studies, some enhanced surgical techniques have continued to emerge over the last decade. In 2006, Stummer et al conducted the only RCT to date on the use of 5-aminolevulinic acid for fluorescence-guided tumor resection, showing that enhanced resection of HGGs with this agent improves 6-month progression-free survival. 31 Recent years have also shown the emergence of studies investigating novel targeted therapies, including anti-angiogenic strategies, 32-36 molecular 
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pathway inhibitors, 37, 38 and viral vectors 39 or stem cells 40, 41 for targeted drug delivery.
While the citation classics identified in the present study represent highly influential work in neuro-oncology, our search may not have captured all of the important articles in the field. In particular, recent articles that do not have sufficient time to accumulate citations and older articles where early citations may not be reliably indexed in modern databases would likely not be reflected in this analysis. It is also possible that our search terms may have missed articles relevant to neuro-oncology, although we used broad terms in order to reduce this possibility. Furthermore, setting a citation cutoff too high may miss important articles, yet a cutoff too low can be excessively inclusive. A cutoff of 400 citations has historically been used to define a citation classic, 4 and analyses across multiple disciplines have commonly utilized this threshold or examined a subset of the highest cited works. In our analysis, we utilized an initial cutoff of 400 citations, then selected the top 100 cited classics among this list in order to provide a comprehensive but practical list of high impact articles in the field of neuro-oncology.
Overall, this study provides an important analysis of the historical trends in the field of neuro-oncology. Our findings suggest that there is currently significant interest among the scientific community in better understanding tumor pathogenesis along with developing nonsurgical therapies for the treatment of CNS tumors with great value placed on high-quality clinical trials and fundamental laboratory investigations. These will likely be areas of continued growth and interest in the emerging future.
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